Publications

My publications cover the range of areas I have worked in across the health economics of cancer care.

  1. Pearce A, Carter S, Frazer HML, Houssami N, Macheras-Magias M, Webb G, Marinovich ML. (2025). Implementing artificial intelligence in breast cancer screening: Women’s preferences.  Cancer, 131(9):e35859
  2. Keramat SA, Comans T, Pearce A, Basri R, Hashmi R, Dissanayaka NN. (2025). Psychological distress and productivity loss: a longitudinal analysis of Australian working adults. Eur J Health Economics. https://doi.org/10.1007/s10198-025-01764-9
  3. Lei S, Venning B, Pearce A, Lee A, Emery J. (2025). Patterns of diagnostic testing for oesophagogastric cancer-related symptoms in Australian General Practice. British Journal of General Practice. 2024.0621
  4. Wu VS, Smith AB, Russell H, Bamgboje-Ayodele A, Beatty L, Pearce A, Dhillon H, Shaw J, Antony J, Fardell J, Pangeni A, Dixon C, Rincones O, Langdon L, Costa D, Girgis A. (2025). Assessing the impact of a self-guided digital intervention for fear of cancer recurrence (iConquerFear) in ovarian cancer survivors: a pilot randomised waitlist-controlled trial. BMC Cancer; 25, 527.
  5. Salisbury A, Winston H, Johnson A, Pearce A, Howard K, Norris S. (2025). Public perspectives around prenatal screening of chromosomal abnormalities: A focus group study comparing metropolitan and rural/regional areas in Australia. ANZ Journal of Obstetrics and Gynaecology. Early online 7th Feb 2025.
  6. Salisbury A, Norris S, Pearce A, Howard K. (2025) Australian preferences for prenatal screening: a discrete choice experiment comparing metropolitan and rural/regional areas. Applied Health Economics and Health Policy. Early online, 17th January 2025.
  7. Salisbury A, Pearce A, Howard K, Norris S. (2024) Impact of Structural Differences on the Modeled Cost-Effectiveness of Noninvasive Prenatal Testing. Medical Decision Making. 2024;44(7):811-827.
  8. Smith AB, Girgis A, Taylor N, Pearce A, Liu J, Shepherd HL, Wu VS, Garvey G, Kirsten L, Zakhary I, Ee C, Ewald D, Miller A, Shaw J. (2024) Step-by-step: A clinical pathway for stepped care management of fear of cancer recurrence—results of a three-round online delphi consensus process with Australian health professionals and researchers. Journal of Cancer Survivorship. 2024. Early online, 10th Oct 2024.
  9. Salisbury A, Ciardi J, Norman R, Smit AK, Cust AE, Low C, Caruana M, Gordon L, Canfell K, Steinberg J, Pearce A. (2024). Public preferences for genetic and genomic risk-informed chronic disease screening and early detection: A systematic review of discrete choice experiments. Applied Health Economics and Health Policy. Online first, 25th June 2024.
  10. Sweeney LA, Sharp L, McMullin C, Pearce A, Molcho M. (2024) Service Access and Supportive Care Experiences among Urban and Rural Cancer Survivors: Informing Social Work Practice, Health & Social Work, 2024, hlae033.
  11. Newman B, Bowden J, Jessup R, Christie LJ, Livingstone A, Sarkies M, Killedar A, Vleeskens C, Sarwar Mashreka, Tieu T, Chamberlain S, Harrison R, Pearce A. (2024). Engaging with health consumers in scientific conferences – As partners not bystanders. Health Expectations. 27(4):e14147
  12. Goldsbury DE, Haywood P, Pearce A, Collins LG, Karikios D, Canfell K, Steinberg J, Weber MF. (2024). Out-of-pocket health care expenses for people with and without cancer, New South Wales, 2020: a cross-sectional study. Medical Journal of Australia. 221(2): 94-102.
  13. Venning B, Pearce A, De Abreu Lourenco R, Hall R, Bergin R, Lee A, Donohoe K, Emery J. (2024). Patient preferences for investigating cancer-related symptoms in Australian General Practice: A discrete choice experiment. British Journal of General Practice. Online first, 23rd Feb 2024.
  14. Jollife L, Christie LJ, Fearn N, Nohrenberg M, Liu R, Williams JF, Parsons MW, Pearce A. (2024). A systematic review of discrete choice experiments in stroke rehabilitation. Topics in Stroke Rehabilitation. Online first, 19th Feb 2024.
  15. Christie LJ, Rendell R, Fearn N, Descallar J, McCluskey A, Pearce A, Wong L, Lovarini M (2023). Increasing the delivery of upper limb constraint-induced movement therapy programs for stroke and brain injury survivors: evaluation of the ACTIveARM Project. Disability and Rehabilitation. Online first 22nd Dec 2023.
  16. Howard K, Norris S, Salisbury A, Pearce A, Hay L, Stapleton B, Lean C, Last A, Kwedza R, White K, Rushton S. (2024). Women’s preferences for hypofractionated radiation therapy for treatment of early-stage breast cancer: a discrete choice experiment. International Journal of Radiation Oncology, Biology, Physics. Online first, 6th Dec 2023.
  17. van Til J, Pearce A, Ozdemir S, Hollin I, Peay H, Wu A, Ostermann J, Deal K, Craig B (2023). Role preferences in medical decision making: Relevance and implications for health preference research.The Patient. Online first 24th Oct 2023.
  18. Pearce A, Scarfe J, Jones M, Cashmore A, Milat A, Barnes L, Passey M (2023). Study protocol of an economic evaluation embedded in the Midwives and Obstetricians Helping Mothers to Quit Smoking (MOHMQuit) trial. BMC Health Services Research.23:939.
  19. Ortega-Ortega M, Hanly P, Pearce A, Soerjomataram I, Sharp L . (2023) Projected impact on labour productivity costs of cancer-related premature mortality in Europe 2018-2040. Applied Health Economics and Health Policy.  21:877-889.
  20. Venchiarutti RL, Pearce A, Mathers L, Dawson T, Ch’ng S, Shannon K, Clark JR, Palme CE. (2023) Travel-associated cost savings to patients and the health system through provision of specialist head and neck surgery outreach clinics in rural New South Wales, Australia. Australian Journal of Rural Health. 00:1-12.
  21. Henry G, Webb A, Galea C, Pearce A, Balde I, Garrity F, Marmont S, Espie J, Badawi N, McIntyre S. (2023). Out of pocket costs for families and people living with cerebral palsy in Australia.PLOS One. 18(7):e0288865.
  22. De Camargo Cancela M, Leandro Bezerra de Souza D, Felipe Leite Martins, L, Borges L, Orlando Schilithz A, Hanly P, Sharp L, Pearce A, Soejorataram I (2023). Can the sustainable development goals for cancer be met in Brazil? A population-based study.Frontiers in Oncology. 12:1060608.
  23. De Camargo Cancela M, Dos Santos JEM, Borges Lopes de Souza L, Felipe Leite Martins L, Bezerra de Souza D, Barchuk A, Hanly P, Sharp L, Soerjomataram I, Pearce A. (2023). The economic impact of cancer mortality among working age individuals in Brazil from 2001 to 2030. Cancer Epidemiology. 86:102438.
  24. Venning B, Bergin R, Pearce A, Lee A, Emery J. Factors affecting patient decisions to undergo testing for cancer symptoms: an exploratory qualitative study in Australian General Practice. BJGP Open. 7(1).
  25. Barnes L, Longman J, Adams C, Paul C, Atkins L, Bonevski B, Cashmore A, Twyman L, Bailie R, Pearce A, Barker D, Milat A, Dorling J, Nicholl M, Passey M. (2022). The MOHMQuit (Midwives and Obstetricians Helping Mothers to Quit Smoking) Trial: protocol for a stepped-wedge implementation trial to improve best practice smoking cessation support in public antenatal care services. Implementation Science. 17:79.
  26. Faaij M, Schoormans D, Pearce A. (2022). Work, daily activities and leisure after cancer. European Journal of Cancer Care. 31(4)e13596.
  27. Christie L, Fearn N, McCluskey A, Lovarini M, Rendell R, Pearce A. (2022). Cost effectiveness of constraint induced movement therapy implementation in neurorehabilitation: The ACTIveARM Project. Pharmacoeconomics Open. 6(3):437-450.
  28. Goldsbury DE, Feletto E, Weber MF, Haywood P, Pearce A, Lew JB, Worthington J, He E, Steinberg J, O’Connell DL, Canfell K. (2022). Health system costs and days in hospital for colorectal cancer patients in New South Wales, Australia. PLOS One. 16(11):e0260088.
  29. Hassett L, Jennings M, Brady B, Pinheiro M, Haynes A, Sidhu B, Christie L, Dennis S, Pearce A, Howard K, Greaves C & Sherrington C. (2022). Brief physical activity counselling by physiotherapists (BEHAVIOUR): protocol for an effectiveness-implementation hybrid type II cluster randomised controlled trial. Implementation Science Communications. 3(39).
  30. Sigurdson S, Harrison M, Pearce A, Richardson H, Zaza K, Brundage M. (2022). One fraction size does not fit all: Patient preferences for hypofractionated radiation therapy from a discrete choice experiment. Practical Radiation Oncology. 12(1):e24-e33. 
  31. Marinovich L, Wylie E, Lotter W, Pearce A, Carter S, Lund H, Waddell A, Kim J, Pereira G, Lee C, Zackrisson S, Brennan M, Houssami N. (2022). Artificial intelligence (AI) to enhance breast cancer screening: protocol for a population-based cohort study of cancer detection. BMJ Open. 12:
  32. Shaw J, Allison K, Cuddy J, Lindsay T, Grimison P, Shepherd H, Butow P, Shaw T, Baychek K, The ADAPT Program Group, Kelly B. (2022). Development, acceptability and uptake of an online communication skills education program targeting challenging conversations for oncology health professionals related to identifying and responding to anxiety and depression.BMC Health Services Research. 22(132). 
  33. Ortega-Ortega M, Hanly P, Pearce A, Soerjomataram I, Sharp L. (2021). Paid and unpaid productivity losses due to premature mortality from cancer in Europe in 2018. International Journal of Cancer. 150(4):580-593.
  34. Gelfand A, Sou J, Sawatzky R, Prescott K, Pearce A, Anis A H, Lee C, Zhang W. (2021). Valuation of lost productivity in caregivers: a validation study. Frontiers in Psychology (Organizational Psychology section).12:727871.
  35. Williams J, Pearce A, Smith A. (2021). A systematic review of fear of cancer recurrence related healthcare use and intervention cost-effectiveness. Psycho-Oncology. 30(8):1185–
  36. Yu A, Street D, Viney R, Goodall S, Pearce A, Haywood Ph, Haas M, Battaglini E, Goldstein D, Timmins H, Park S. (2021). Clinical assessment of chemotherapy-induced peripheral neuropathy: a discrete choice experiment of patient preferences.Supportive Care in Cancer. 29:6379–6387.
  37. Yim J, Shaw J, Viney R, Arora S, Ezendam N, Pearce A. (2021). Investigating the association between self-reported comorbid anxiety and depression and health service use in cancer survivors.  39:681–690.
  38. Pearce A, Harrison M, Watson V, Street D, Howard K, Bansback N, Bryan S. (2021). Respondent understanding in discrete choice experiments: A scoping review. The Patient. 14:17-53.
  39. Hanly P, Ortega Ortega M, Pearce A, Soerjomataram I, Sharp L. (2020). Advances in the methodological approach to friction period estimation: A European perspective. Social Science and Medicine. 264:
  40. Geerligs L, Shepherd H, Putow P, Shaw J, Masya L, Cuddy J, ADAPT Program Group, Ranking N. (2021). What factors influence organisational readiness for change? Implementation of the Australian clinical pathway for the screening, assessment and management of anxiety and depression in adult cancer patients (ADAPT CP). Supportive Care in Cancer. 29(6):3235-3244.
  41. Manipis K, Goodall S, Hanly P, Viney R, Pearce A. (2020). Employer survey to estimate the productivity friction period. European Journal of Health Economics. 22: 255-266.
  42. Mols F, Tomalin B, Pearce A, Kaambwa B, Koczwara B. (2020). Financial toxicity and employment status in cancer survivors. A systematic literature review. Supportive Care in Cancer. 28, 5693-5708.
  43. Pearce A, Mulhern B, Watson V, Viney R. (2020). How are debriefing questions used in health discrete choice experiments?An online survey. Value in Health. 23(3), 289-293.
  44. Smith A, Bamgboje-Ayodele A, Butow P, Klein B, Turner J, Sharpe L, Fardell J, Beatty L, Pearce A, Thewes B, Beith J, Costa D, Community Advisory Group Members and Girgis A. (2020). Development and usability evaluation of an online self-management intervention for fear of cancer recurrence (iConquerFear). Psycho-Oncology. 29(1).
  45. Geerligs L, Shepherd H, Rankin N, Masya L, Shaw JM, Price MA, Dhillon H, Dolan C, Prest G, The ADAPT Program Group, Butow P. (2020). The value of real-world testing: a qualitative feasibility study to explore staff and organisational barriers and strategies to support implementation of a clinical pathway for the management of anxiety and depression in adult cancer patients.Pilot and Feasibility Studies. 6(109). 
  46. Barchuk A, Bespalov A, Huhtala H, Chimed T, Belyaev A, Moore M, Anttila A, Auvinen A, Pearce A, Soerjomataram I. (2019). Productivity losses associated with premature mortality due to cancer in Russia: A population-wide study covering 2001-2030. Scandinavian Journal of Public Health. 47(5). 
  47. Pearce A, Tomalin B, Kaambwa B, Horevoorts N, Duijts S, Mols F, van de Poll-Franse L, Koczwara B. (2019). Financial toxicity is more than costs of care: the relationship between employment and financial toxicity in long-term cancer survivors. Journal of Cancer Survivorship. 13:10-20. 
  48. Pearce A, Sharp L, Hanly P, Barchuk A, Bray F, de Camargo Cancel M, Gupta P, Meheus F, Qiao YL, Sitas F, Wang SM, Soerjomataram I (2018). Productivity losses due to premature mortality from cancer in Brazil, Russia, India, China and South Africa (BRICS): A population-based comparison. Cancer Epidemiology. 53:27-34.
  49. Butow P, Shaw J, Shepherd H, et al, and The ADAPT Program Group (2018). Comparison of implementation strategies to influence adherence to the clinical pathway for screening, assessment and management of anxiety and depression in adult cancer patients (ADAPT CP): Study protocol of a cluster randomised controlled trial.BMC Cancer. 18(1077). 
  50. Shaw J, Pearce A, Lopez AL, Price M. (2018). Clinical anxiety disorders in the context of cancer: a scoping review of impact on resource use and health care costs. European Journal of Cancer Care. 27(5).
  51. Pearce A, Haas M, Viney R, Pearson SA, Haywood P, Brown C, Ward R (2017). Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study. PLOS One. 12(10): e0184360.
  52. Hanly P, Pearce A, Sharp L (2017). Cancer and productivity loss in the Irish economy: An employer’s perspective. Irish Journal of Management. 36(1):5-20.
  53. Thomas AA, Pearce A, O’Neill C, Molcho M, Sharp L. (2016). Urban-rural differences in cancer-directed surgery and survival of patients with non-small cell lung cancer. Journal of Epidemiology and Community Health. 71:468-474.
  54. Pearce A, Bradley C, Hanly P, O’Neill C, Thomas AA, Molcho M, Sharp L. (2016). Projecting productivity losses for cancer-related mortality 2011 – 2030. BMC Cancer. 16:804.
  55. Thomas AA, Pearce A, Sharp L, Gardiner RA, Chambers S, Aitken JA, Molcho M, Baade P. (2016). Socioeconomic disadvantage but not remoteness affects short-term survival in prostate cancer: A population-based study using competing risks. Asia-Pacific Journal of Clinical Oncology. 13:31-40.
  56. Pearce A, Ryan F (joint first author), Drummond F, Thomas AA, Timmons A, Sharp L (2015). Comparing the costs of three prostate cancer follow-up strategies: a cost minimisation analysis. Supportive Care in Cancer. 24:879-886.
  57. Pearce A, Hanly P, Timmons A, Walsh PM, O’Neill C, O’Sullivan E, Gooberman-Hill R, Thomas AA, Gallagher P, Sharp L (2015). Productivity losses associated with head and neck cancer using the Human Capital and Friction Cost approaches. Applied Health Economics and Health Policy. 13:359-367.
  58. Pearce AM, Timmons A, O’Sullivan E, Gallagher P, Gooberman-Hill R, Thomas AA, Molcho M, Butow P, Sharp L (2015). Long-term workforce participation patterns following head and neck cancer. Journal of Cancer Survivorship. 9(1):30-39.
  59. Pearce A, Haas M, Viney R, Haywood P, Pearson SA, van Gool K, Srasuebkul P, Ward R (2014). Can administrative data be used to measure chemotherapy side effects?Expert Review of Pharmacoeconomics and Outcomes Research. 15(2):215-222..
  60. Sharp L, Deady S, Gallagher P, Molcho M, Pearce A, Thomas AA, Timmons A, Comber H (2014). The magnitude and characteristics of the population of cancer survivors: using population-based estimates of cancer prevalence to inform service planning for survivorship care.BMC Cancer. 14:767.
  61. Thomas AA, Gallagher P, O’Ceilleachair A, Pearce A, Sharp L, Molcho M (2014). Distance from treating hospital and colorectal cancer survivors’ quality of life: a gendered analysis. Supportive Care in Cancer.23(3):741-751.
  62. Hanly P, Pearce A, Sharp L (2014). The cost of premature cancer-related mortality: a review and assessment of the evidence. Expert Review of Pharmacoeconomics and Outcomes Research. 14(3):355-377.
  63. Thomas AA, Timmons A, Molcho M, Pearce A, Gallagher P, Butow P, O’Sullivan E, Gooberman-Hill R, O’Neill C, Sharp L (2014). Quality of life in urban and rural settings: A study of head and neck cancer survivors. Oral Oncology. 50(7):679-682.
  64. Pearce A, Haas M, Viney R (2013). Are the true impacts of adverse events considered in economic models of antineoplastic drugs? A systematic review.Journal of Applied Health Economics and Health Policy. 11(6):619-637.
  65. Noushi F, Spillane AJ, Uren RF, Cooper R, Allwright S, Snook KL, Gillet D, Pearce A, Gebski V (2013). High discordance rates between sub-areolar and peri-tumoural breast lymphoscintigraphy. European Journal of Surgical Oncology. 39(10):1053-1060.
  66. Pearce A, Van Gool K, Haywood P, Haas M (2013). Delays in access to affordable medicines – putting policy into perspective: Authors’ response. Australian Health Review. 38(1):16-17.
  67. Pearce A, Van Gool K, Haywood P, Haas M (2012). Delays in access to affordable medicines – putting policy into perspective. Australian Health Review. 36(4):412-418.
  68. Pearce A, Smead J, Cameron I (2012).Retrospective cohort study of accident outcomes for individuals who have successfully undergone driver assessment following stroke.  Australian Occupational Therapy Journal. 59(1):56-62.